Cargando…
Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually insufficient to change the poor prognosis. Moreover, apart from staging and histological classification, there are no...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672377/ https://www.ncbi.nlm.nih.gov/pubmed/38002620 http://dx.doi.org/10.3390/jcm12227006 |
_version_ | 1785140376918556672 |
---|---|
author | Sorino, Claudio Mondoni, Michele Marchetti, Giampietro Agati, Sergio Inchingolo, Riccardo Mei, Federico Flamini, Sara Lococo, Filippo Feller-Kopman, David |
author_facet | Sorino, Claudio Mondoni, Michele Marchetti, Giampietro Agati, Sergio Inchingolo, Riccardo Mei, Federico Flamini, Sara Lococo, Filippo Feller-Kopman, David |
author_sort | Sorino, Claudio |
collection | PubMed |
description | Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually insufficient to change the poor prognosis. Moreover, apart from staging and histological classification, there are no validated predictors of its response to treatment or its long-term outcomes. Numerous studies have investigated minimally invasive biomarkers in pleural fluid or blood to aid in earlier diagnosis and prognostic assessment of PM. The most studied marker in pleural effusion is mesothelin, which exhibits good specificity but low sensitivity, especially for non-epithelioid PM. Other biomarkers found in pleural fluid include fibulin-3, hyaluronan, microRNAs, and CYFRA-21.1, which have lower diagnostic capabilities but provide prognostic information and have potential roles as therapeutic targets. Serum is the most investigated matrix for biomarkers of PM. Several serum biomarkers in PM have been studied, with mesothelin, osteopontin, and fibulin-3 being the most often tested. A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker in patients with suspected mesothelioma. With different serum and pleural fluid cut-offs, it provides useful information on the diagnosis, prognosis, follow-up, and response to therapy in epithelioid PM. Panels combining different markers and proteomics technologies show promise in terms of improving clinical performance in the diagnosis and monitoring of mesothelioma patients. However, there is still no evidence that early detection can improve the treatment outcomes of PM patients. |
format | Online Article Text |
id | pubmed-10672377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106723772023-11-09 Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers Sorino, Claudio Mondoni, Michele Marchetti, Giampietro Agati, Sergio Inchingolo, Riccardo Mei, Federico Flamini, Sara Lococo, Filippo Feller-Kopman, David J Clin Med Review Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually insufficient to change the poor prognosis. Moreover, apart from staging and histological classification, there are no validated predictors of its response to treatment or its long-term outcomes. Numerous studies have investigated minimally invasive biomarkers in pleural fluid or blood to aid in earlier diagnosis and prognostic assessment of PM. The most studied marker in pleural effusion is mesothelin, which exhibits good specificity but low sensitivity, especially for non-epithelioid PM. Other biomarkers found in pleural fluid include fibulin-3, hyaluronan, microRNAs, and CYFRA-21.1, which have lower diagnostic capabilities but provide prognostic information and have potential roles as therapeutic targets. Serum is the most investigated matrix for biomarkers of PM. Several serum biomarkers in PM have been studied, with mesothelin, osteopontin, and fibulin-3 being the most often tested. A soluble mesothelin-related peptide (SMRP) is the only FDA-approved biomarker in patients with suspected mesothelioma. With different serum and pleural fluid cut-offs, it provides useful information on the diagnosis, prognosis, follow-up, and response to therapy in epithelioid PM. Panels combining different markers and proteomics technologies show promise in terms of improving clinical performance in the diagnosis and monitoring of mesothelioma patients. However, there is still no evidence that early detection can improve the treatment outcomes of PM patients. MDPI 2023-11-09 /pmc/articles/PMC10672377/ /pubmed/38002620 http://dx.doi.org/10.3390/jcm12227006 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sorino, Claudio Mondoni, Michele Marchetti, Giampietro Agati, Sergio Inchingolo, Riccardo Mei, Federico Flamini, Sara Lococo, Filippo Feller-Kopman, David Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title | Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title_full | Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title_fullStr | Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title_full_unstemmed | Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title_short | Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers |
title_sort | pleural mesothelioma: advances in blood and pleural biomarkers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672377/ https://www.ncbi.nlm.nih.gov/pubmed/38002620 http://dx.doi.org/10.3390/jcm12227006 |
work_keys_str_mv | AT sorinoclaudio pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT mondonimichele pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT marchettigiampietro pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT agatisergio pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT inchingoloriccardo pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT meifederico pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT flaminisara pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT lococofilippo pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers AT fellerkopmandavid pleuralmesotheliomaadvancesinbloodandpleuralbiomarkers |